UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line

International journal of antimicrobial agents, 2020-08, Vol.56 (2), p.106017-106017, Article 106017

2020

Link zum Volltext

Verfügbarkeit prüfen

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Journal of acquired immune deficiency syndromes (1999), 2021-11, Vol.88 (3), p.234

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital

Virology journal, 2023-09, Vol.20 (1), p.214-214, Article 214

2023

Link zum Volltext

Verfügbarkeit prüfen

Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Infection, 2020-04, Vol.48 (2), p.309-310

2020

Link zum Volltext

Verfügbarkeit prüfen

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Viruses, 2023-04, Vol.15 (5), p.1046

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC infectious diseases, 2019-01, Vol.19 (1), p.59-9, Article 59

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

Viruses, 2023-03, Vol.15 (3), p.762

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

Viruses, 2022-01, Vol.14 (1), p.163

2022

Link zum Volltext

Verfügbarkeit prüfen

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Infectious medicine, 2023-06, Vol.2 (2), p.143-147

2023

Link zum Volltext

Verfügbarkeit prüfen

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

HIV research & clinical practice, 2022-12, Vol.23 (1), p.28-36

2022

Link zum Volltext

Verfügbarkeit prüfen

Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections

Journal of personalized medicine, 2022-04, Vol.12 (4), p.650

2022

Link zum Volltext

Verfügbarkeit prüfen

Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study

HIV research & clinical practice, 2021-09, Vol.22 (4), p.96-101

2021

Link zum Volltext

Verfügbarkeit prüfen

Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak

Diagnostics (Basel), 2021-06, Vol.11 (7), p.1154

2021

Link zum Volltext

Verfügbarkeit prüfen

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients

HIV research & clinical practice, 2019-05, Vol.20 (3), p.92-98

2019

Link zum Volltext

Verfügbarkeit prüfen

Reduced probability of improving viro‐immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study

Immunity, Inflammation and Disease, 2023-02, Vol.11 (2), p.e778-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Automated Quantitative Lung CT Improves Prognostication in Non-ICU COVID-19 Patients beyond Conventional Biomarkers of Disease

Diagnostics (Basel), 2021-11, Vol.11 (11), p.2125

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Infectious diseases and therapy, 2019-09, Vol.8 (3), p.453-462

2019

Link zum Volltext

Verfügbarkeit prüfen

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

Journal of antimicrobial chemotherapy, 2019-05, Vol.74 (5), p.1461-1463

2019

Link zum Volltext

Verfügbarkeit prüfen

Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection

Journal of medical virology, 2020-10, Vol.92 (10), p.1787-1788

2020

Link zum Volltext

Verfügbarkeit prüfen

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study

Journal of antimicrobial chemotherapy, 2023-09, Vol.78 (9), p.2315-2322

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-life findings on the impact of the COVID-19 pandemic on HIV care

Antiviral therapy, 2021-05, Vol.26 (3-5), p.84-86

2021

Link zum Volltext

Verfügbarkeit prüfen

No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir

AIDS (London), 2020-05, Vol.34 (6), p.956-957

2020

Link zum Volltext

Verfügbarkeit prüfen

Still Much to Learn About the Diagnostic Role of SARS-CoV-2 Antibody Detection

Clinical infectious diseases, 2020-11, Vol.71 (16), p.2299-2300

2020

Link zum Volltext

Verfügbarkeit prüfen

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

Expert review of anti-infective therapy, 2020-04, Vol.18 (4), p.279-292

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(79)
Berichte
(4)

Sprache

Englisch
(83)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital

Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections

Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study

Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients

Reduced probability of improving viro‐immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study

Automated Quantitative Lung CT Improves Prognostication in Non-ICU COVID-19 Patients beyond Conventional Biomarkers of Disease

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study

Real-life findings on the impact of the COVID-19 pandemic on HIV care

No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir

Still Much to Learn About the Diagnostic Role of SARS-CoV-2 Antibody Detection

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

Suchergebnisse filtern